OpenNeedle Ask your own

Question explored with the scientific record

Conversation so far

  1. 1 Is Rsv vaccines worth it for a healthy 72 year old
  2. 2 What does gbs from Rsv vaccine do to you

Answered on this page ↓

What does gbs from Rsv vaccine do to you

Nov 13, 2026 · 5 sources used · OpenNeedle synthesis
The short version: GBS is an immune attack on your nerves that causes weakness, and it can be serious, but most people recover over weeks to months.

GBS is your immune system attacking the myelin sheath or the axon of your peripheral nerves. The classic picture is ascending weakness, starting in the legs and moving up, with absent reflexes [2]. It can progress to where you cannot walk, and in severe cases it reaches the breathing muscles. The retrieved records show a range: one patient had grade 1/5 strength in the legs and 4/5 in the arms [4], another needed no ventilator and improved on IVIG [4], and a third recovered full ambulation by three months with supportive care alone [3]. Autonomic involvement (blood pressure swings, fast heart rate) tracks with worse motor disability in children [1]. The most informative comparison, vaccinated versus unvaccinated over time, is not in these records. What is here is a post-licensure hospital-record analysis estimating about 11 extra GBS cases per million RSV vaccinations overall, and about 18 per million for the Pfizer product [5]. That is a real signal, not a rumor, but it is rare.

OutcomeWhat the records show
Typical courseAscending weakness, absent reflexes [2]
Severe caseGrade 1/5 legs, 4/5 arms [4]
Milder courseNo ventilator, improved on IVIG [4]
Recovery without treatmentFull ambulation by 3 months [3]
Excess GBS, all RSV vaccines~11 per million doses [5]
Excess GBS, Pfizer product~18 per million doses [5]

The honest limit: these are case reports and one surveillance analysis, not a long-term follow-up of people who developed GBS after an RSV shot. Nobody in these records tracked those patients for a year or more. If you get GBS, the acute phase is the danger window, and recovery is usually slow but real.

My call: GBS after an RSV vaccine is rare and usually recoverable, but it is a genuine harm and the long-term data on these specific patients does not exist in what I can see. Confidence: moderate on the clinical picture, low on long-term outcomes.

Keep digging

Sources used 5

  1. Autonomic Dysfunction in Childhood Guillain-Barré Syndrome Journal of Child Neurology (2012) Thin

    This study investigates the correlation between autonomic dysfunction and motor impairment in children hospitalized with Guillain-Barre syndrome, finding significant associations between hypertension, tachycardia, and the severity of motor disability.

    DOI: 10.1177/0883073811420872
  2. Magnetic resonance imaging of lower limb musculature in acute motor axonal neuropathy Journal of Neurology (2011) Thin

    This study presents a detailed examination of a 74-year-old patient with acute motor axonal neuropathy (AMAN) using serial magnetic resonance imaging (MRI) to assess muscle denervation and recovery over two years, highlighting the correlation between MRI findings and clinical-el…

    DOI: 10.1007/s00415-011-6309-1
  3. Guillain-Barre Syndrome Secondary to COVID-19: A case report and short review of other published cases RRNMF Neuromuscular Journal (2022) primary study Strong

    A 37-year-old man developed para-infectious Guillain-Barré syndrome (AIDP) during active COVID-19 and recovered full ambulation by three months with supportive care alone, without IVIG or plasmapheresis.

    DOI: 10.17161/rrnmf.v3i1.15770
  4. Aplastic anemia and guillain-barre syndrome after COVID-19 mRNA vaccination Journal of Clinical Images and Medical Case Reports (2024) primary study Strong

    A 40-year-old man developed severe aplastic anemia 18 days after a Pfizer-BioNTech mRNA booster and AMSAN-variant Guillain-Barré syndrome on day 7 of admission, with no alternative cause identified.

    DOI: 10.52768/2766-7820/3189
  5. Efficacy, effectiveness, and safety of respiratory syncytial virus vaccines in adults: Evidence from clinical trials and real-world effectiveness studies The Southwest Journal of Medicine (2026) narrative review Strong

    Current RSV vaccines in adults ≥60 years show clinically meaningful trial efficacy and real-world effectiveness against RSV lower respiratory tract disease and hospitalization, with waning protection and small rare neurologic safety signals.

    DOI: 10.12746/swjm.v14i60.1649

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question →